Juvaris "goes virtual", as adjuvant platform and management goes to Colby
This article was originally published in Scrip
Executive Summary
Juvaris BioTherapeutics, a privately held company with vaccine technology based in Burlingame, California, has completed a licence agreement for its technology in the area of human health, after it had already licensed the same technology to Bayer for animal health in 2008. The firm will now go virtual, in order to capture the value of future efforts of the two licensees – and its CEO Grant Pickering, in addition to providing continuing oversight, will focus on being on executive-in-residence at one of its venture backers (Kleiner Caulfield & Byers).
You may also be interested in...
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Money talks: Verastem leverages IPO to build cancer stem cell pipeline
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.